Ascendia Pharmaceutical Solutions
North Brunswick
About Ascendia Pharmaceutical Solutions
Ascendia Pharmaceutical Solutions is a US-based specialty CDMO that offers a comprehensive suite of DP formulation development and manufacturing services for preclinical- and clinical-stage drug candidates. It specializes in improving the solubility, bioavailability and/or stability of both small molecule and biologic drugs using its suite of nanotechnology platforms. Ascendia formulates products for injectable, oral, topical and transmucosal/ophthalmic routes of administration. The company has four technology platforms - EmulSol(r) for producing nano/micro-emulsions, AmorSol(r) for creating amorphous solid dispersions, NanoSol(r) for formulating nanoparticles, and LipidSol(r) for liposome and LNP formulations. Ascendia has a cGMP facility that scale-up formulations for tox/IND-enabling studies and also supply clinical trial materials in its aseptic and non-aseptic manufacturing suites.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $7.5M
- Last round: Series Unknown (Jun 2025)
- Website: ascendiacdmo.com
- Phone: 732-640-0058
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ascendia-pharmaceutical-solutions-56369 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.